

Neutrophil-to-lymphocyte ratio post-hypofractionated radiation therapy in soft tissue sarcomas is a prognostic biomarker for recurrence and metastasi



NLR value



 5.33 ± 4.2


Constanza Martinez¹, Rie Asso¹, Neelabh Rastogi², Carolyn Freeman¹, Fabio Cury¹.

1. Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada. 2. Department of Medicine, McGill University, Montreal, Quebec, Canada.

Background

The neutrophil-to-lymphocyte ratio (NLR) is a measure of systemic inflammation, and in soft tissue sarcomas (STS) has been shown to be a prognostic marker for treatment response and outcomes 1-3.

Purpose



Materials and methods



Single center (McGill University Health Care Centre) retrospective data collection between 2016 and 2023.



Patients treated with pre-operatively hypofractionated RT (HFRT) with 30 Gy in 5 fractions and who had complete blood counts (CBCs) within 6 months post-RT were included



NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count and dichotomized the variable into ≤4 and >4




Univariable and multivariable logistic regression analyses, adjusting for age, gender, tumor size, and histology were used.

Results 40 patients with CBC 6mo post-HFRT


Mean age (mean)	66 years
Gender (n %)	
Female	17 (42.5)
Male	23 (57.5)
Mean tumor size (mean) Histology (%)	7.1. cm
Myxofibrosarcoma	17.5
Leiomyosarcoma	7.5
Pleomorphic spindle cell sarcoma	10
Myxoid liposarcoma	5

NLR and association with outcomes: The median follow-up was 15.4 months

Table 2. Multivariable analysis of recurrence and metastasis with NLR OR 95% CI P-value NLR (> or < 4)[1.7-51] 7.73 0.034*



0.28



Time (years)

Figure 1. Mean NLR

Conclusion: This is the first study to assess NLR as a prognostic biomarker in STS treated with pre-operative radiotherapy. An NLR >4 was prognostic for recurrence and distant metastasis, but not for overall survival.

References: 1. Fiore, et al. Preoperative Neutrophil-to-Lymphocyte Ratio and a New Inflammatory Biomarkers Prognostic Index for Primary Retroperitoneal Sarcomas: Retrospective Monocentric Study. Clin Cancer Res 1 February 2023. 2. García-Ortega DY, et al. Neutrophil/lymphocyte ratio is associated with survival in synovial sarcoma. Surg Oncol. 2018;27(3):551555. 3. Sato Y, et al. Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. Cancers (Basel). 2021;13(24):6266.

Histology